HighTower Advisors’s SANGAMO THERAPEUTICS INC SGMO Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | – | Sell |
-706,481
| Closed | -$174K | – | 3994 |
|
|
2026
Q1 | $174K | Buy |
706,481
+2,025
| +0.3% | +$806 | ﹤0.01% | 3530 |
|
|
2025
Q4 | $296K | Sell |
704,456
-39,650
| -5% | -$21K | ﹤0.01% | 3059 |
|
|
2025
Q3 | $501K | Sell |
744,106
-662
| -0.1% | -$357 | ﹤0.01% | 2619 |
|
|
2025
Q2 | $403K | Sell |
744,768
-15,895
| -2% | -$9.44K | ﹤0.01% | 2703 |
|
|
2025
Q1 | $499K | Buy |
760,663
+3,840
| +0.5% | +$4.07K | ﹤0.01% | 2462 |
|
|
2024
Q4 | $772K | Sell |
756,823
-36,255
| -5% | -$66.3K | ﹤0.01% | 2153 |
|
|
2024
Q3 | $647K | Buy |
793,078
+765
| +0.1% | +$560 | ﹤0.01% | 2209 |
|
|
2024
Q2 | $255K | Buy |
792,313
+4,023
| +0.5% | +$2.17K | ﹤0.01% | 2846 |
|
|
2024
Q1 | $489K | Sell |
788,290
-2,920
| -0.4% | -$2.12K | ﹤0.01% | 2296 |
|
|
2023
Q4 | $382K | Sell |
791,210
-351,930
| -31% | -$162K | ﹤0.01% | 2523 |
|
|
2023
Q3 | $608K | Sell |
1,143,140
-13,725
| -1% | -$14.7K | ﹤0.01% | 2098 |
|
|
2023
Q2 | $1.48M | Buy |
1,156,865
+125,733
| +12% | +$172K | ﹤0.01% | 1526 |
|
|
2023
Q1 | $1.8M | Buy |
1,031,132
+174
| +0% | +$497 | ﹤0.01% | 1346 |
|
|
2022
Q4 | $3.24M | Sell |
1,030,958
-130,967
| -11% | -$508K | 0.01% | 1029 |
|
|
2022
Q3 | $5.64M | Sell |
1,161,925
-5,608
| -0.5% | -$28.8K | 0.02% | 749 |
|
|
2022
Q2 | $4.79M | Buy |
1,167,533
+108,016
| +10% | +$467K | 0.01% | 836 |
|
|
2022
Q1 | $6.17M | Buy |
1,059,517
+115,701
| +12% | +$688K | 0.01% | 784 |
|
|
2021
Q4 | $7.14M | Buy |
943,816
+913,600
| +3,024% | +$7.94M | 0.02% | 738 |
|
|
2021
Q3 | $274K | Sell |
30,216
-5,080
| -14% | -$50.2K | ﹤0.01% | 2481 |
|
|
2021
Q2 | $421K | Buy |
35,296
+1,855
| +6% | +$21K | ﹤0.01% | 2150 |
|
|
2021
Q1 | $418K | Sell |
33,441
-3,544
| -10% | -$47.8K | ﹤0.01% | 2091 |
|
|
2020
Q4 | $578K | Sell |
36,985
-1,750
| -5% | -$20.5K | ﹤0.01% | 1572 |
|
|
2020
Q3 | $368K | Sell |
38,735
-1,996
| -5% | -$21.6K | ﹤0.01% | 1724 |
|
|
2020
Q2 | $364K | Sell |
40,731
-2,642
| -6% | -$24.5K | ﹤0.01% | 1621 |
|
|
2020
Q1 | $279K | Buy |
43,373
+5,972
| +16% | +$44.3K | ﹤0.01% | 1610 |
|
|
2019
Q4 | $313K | Sell |
37,401
-16,175
| -30% | -$149K | ﹤0.01% | 1701 |
|
|
2019
Q3 | $485K | Buy |
53,576
+4,921
| +10% | +$55.2K | ﹤0.01% | 1532 |
|
|
2019
Q2 | $523K | Buy |
48,655
+2,050
| +4% | +$21.8K | ﹤0.01% | 1491 |
|
|
2019
Q1 | $445K | Sell |
46,605
-22,911
| -33% | -$234K | ﹤0.01% | 1515 |
|
|
2018
Q4 | $792K | Sell |
69,516
-22,800
| -25% | -$283K | 0.01% | 1139 |
|
|
2018
Q3 | $1.55M | Buy |
92,316
+68,261
| +284% | +$1.04M | 0.01% | 931 |
|
|
2018
Q2 | $341K | Buy |
24,055
+11,650
| +94% | +$194K | ﹤0.01% | 1623 |
|
|
2018
Q1 | $237K | Buy |
12,405
+100
| +0.8% | +$2.14K | ﹤0.01% | 1801 |
|
|
2017
Q4 | $201K | Sell |
12,305
-800
| -6% | -$11.9K | ﹤0.01% | 1925 |
|
|
2017
Q3 | $198K | Sell |
13,105
-16,300
| -55% | -$180K | ﹤0.01% | 1919 |
|
|
2017
Q2 | $259K | Sell |
29,405
-10,000
| -25% | -$64.2K | ﹤0.01% | 1714 |
|
|
2017
Q1 | $206K | Buy |
39,405
+100
| +0.3% | +$401 | ﹤0.01% | 1758 |
|
|
2016
Q4 | $120K | Buy |
39,305
+8,300
| +27% | +$30.2K | ﹤0.01% | 1759 |
|
|
2016
Q3 | $144K | Buy |
31,005
+400
| +1% | +$2.03K | ﹤0.01% | 1696 |
|
|
2016
Q2 | $178K | Sell |
30,605
-1,500
| -5% | -$9.56K | ﹤0.01% | 1519 |
|
|
2016
Q1 | $193K | Buy |
32,105
+11,600
| +57% | +$69.7K | ﹤0.01% | 1816 |
|
|
2015
Q4 | $187K | Buy |
20,505
+1,000
| +5% | +$7.71K | ﹤0.01% | 1764 |
|
|
2015
Q3 | $110K | Buy |
19,505
+6,403
| +49% | +$52.8K | ﹤0.01% | 1726 |
|
|
2015
Q2 | $145K | Buy |
+13,102
| New | +$169K | ﹤0.01% | 1397 |
|
|
2015
Q1 | – | Sell |
-10,200
| Closed | -$155K | – | 1686 |
|
|
2014
Q4 | $155K | Buy |
+10,200
| New | +$124K | ﹤0.01% | 1427 |
|
Other funds holding SGMO
HighTower Advisors's SGMO Position: Q2 2026 in Review
HighTower Advisors sold out of SANGAMO THERAPEUTICS INC (SGMO) in Q2 2026, closing a stake of 706,481 shares — an estimated $174K sold.
HighTower Advisors first reported a position in SGMO in Q4 2014 and held it in 45 quarters. The position peaked at $7.14M in Q4 2021. 2 funds tracked by Wall St. Rank hold SGMO as of Q2 2026.
- HighTower Advisors reported no remaining SANGAMO THERAPEUTICS INC position as of Q2 2026 after selling out during the quarter.
- HighTower Advisors sold 706,481 SANGAMO THERAPEUTICS INC shares in Q2 2026, an estimated $174K.
- HighTower Advisors first reported a position in SANGAMO THERAPEUTICS INC in Q4 2014 and held it in 45 quarters.
- HighTower Advisors's SANGAMO THERAPEUTICS INC position peaked at $7.14M in Q4 2021.
- 2 funds tracked by Wall St. Rank held SANGAMO THERAPEUTICS INC as of Q2 2026.
Based on HighTower Advisors's 13F filing for Q2 2026, filed 5 Aug 2026.